Trial Profile

A joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French Innovative Leukemia Organization (FILO) evaluating role of Lenalidomide consolidation in patients with Chronic Lymphocytic Leukemia following initial fludarabine, cyclophosphamide and rituximab (FCR) Chemotherapy

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Apr 2025 Results evaluating Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia published in the BMC Cancer.
12 Dec 2023 Status changed from active, no longer recruiting to discontinued because of an acute lymphoblastic leukemia (ALL) warning (3 of 56 patients [5.4%]) in the CLLM1 trial .
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com